Connect with us

Company News

Glenmark Pharmaceuticals Receives ANDA Approval for Atovaquone Oral Suspension

Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Atovaquone Oral Suspension USP, 750 mg/5 mL, a generic version of Mepron Oral Suspension, 750 mg/5 mL, of GlaxoSmithKline LLC. According to IQVIATM sales data, the Mepron Oral Suspension, 750 mg/5 mL market achieved annual sales of approximately USD 119.1 million. Glenmark’s current portfolio consists of 144 products authorized for distribution in the US marketplace and 55 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. – Medical Buyer Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!